A Phase 2 interventional study of Lu AF82422 and Placebo in Multiple System Atrophy, sponsored by H. Lundbeck A/S. Active, not recruiting at 19 sites in 2 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Multiple System Atrophy with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Multiple System Atrophy · United States.
Among the 90 studies in Multiple System Atrophy with a site in United States, this one is the 21st largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2021, is one of 17 in phase 2, reaches primary completion later than 0 of the 31 other live ones, and was the 62nd registered.
207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.
Browse Multiple System Atrophy studies →21 of the 90 studies in Multiple System Atrophy with a site in United States are open now. Recruiting first, the newest first:
Prabesh Kanel · Sites in United States
Ages 45+
MODAG GmbH · Sites in United States
Ages 18–60 · Healthy volunteers
MODAG GmbH · Sites in United States
Ages 50–80 · Healthy volunteers
Teva Branded Pharmaceutical Products R&D LLC · Sites in United States, France, Germany and 4 more countries
Ages 30+
Tiziana Life Sciences LTD · Sites in United States
Ages 30–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 20 · Phase 3 7 · Phase 4 2
First in 1995; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is above the median of 41 across 134 interventional studies indexed under Multiple System Atrophy.
Median enrollment 35 across the 57 interventional studies, 184 across the 31 observational. Of the 53 that completed or were terminated, 19 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 90 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
H. Lundbeck A/S has 7 studies filed under Multiple System Atrophy — fewer than ten, so there is no comparison to draw.
19 of the studies in Multiple System Atrophy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT03042988Vanderbilt University Medical CenterOvernight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension | 2026-11-30 |
| NCT05167721Mayo ClinicRandomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy | 2026-12 |
| NCT02726711Vanderbilt UniversityReduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic | 2026-12 |
| NCT03312556Vanderbilt University Medical CenterTreatment of Supine Hypertension in Autonomic Failure (CPAP) | 2026-12-21 |
Add all 19 to your calendar (.ics) → With an account.
Among the 90 studies in Multiple System Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
This study will consist of a double-blind period (DBP) and will include an optional open-label treatment extension (OLE) period. Participants in the DBP will be randomized to Lu AF82422 or placebo (2:1). All participants entering the OLE will receive Lu AF82422 during the OLE.
Key Inclusion Criteria:
Open-label Extension Entry Criteria
Key Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the DBP will receive Lu AF82422 intravenous (IV) infusion every 4 weeks (Q4W) from Baseline for a minimum 48 weeks up to a maximum 72 weeks. In the optional OLE, all participants will receive Lu AF82422 IV infusion starting on Day 1 of the OLE up to week 188.
Drug: Lu AF82422
Participants in the DBP will receive Lu AF82422 matching placebo IV infusion Q4W from Baseline for a minimum 48 weeks up to a maximum 72 weeks.
Drug: Placebo
Solution for infusion
Solution for infusion
Percentage Slowing of Clinical Progression Based on Change From Baseline in the UMSARS TS at the End of Treatment (EOT) DB Period (DBP)
The primary endpoint assessed disease progression by a Bayesian repeated measures model on UMSARS TS. Reported here is the estimated slowing (%) of clinical progression in participants receiving Lu AF82422 relative to those receiving placebo. UMSARS is a combined clinician and patient-reported outcome assessment developed to provide a surrogate measure of disease progression in multiple system atrophy (MSA). UMSARS TS was obtained by the sum of the items from Part I and Part II. Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks and Part II consists of a clinical examination of key MSA motor signs and symptoms. UMSARS TS score was the sum of all items and ranged from 0 (no impairment) to 104 (severe impairment). A higher score indicated greater impairment.
Time frame: Baseline up to Week 72
Change From Baseline in the UMSARS TS at the End of Treatment (EOT) DBP
UMSARS is a combined clinician and patient-reported scale to assess motor impairment in MSA participants. UMSARS TS was obtained by the sum of the items from Part I and Part II. Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks (12 items) rated on a scale ranging from 0 = not affected to 4 = unable to do the activity. Part I total score ranged between 0 to 48 (higher score indicated greater impairment). Part II consists of a clinical examination of key MSA motor signs and symptoms (14 items) rated on a scale ranging from 0 = normal to 4 = marked/severe impairment. Part II total score ranged between 0 and 56 (higher score indicated greater impairment). UMSARS TS score was the sum of all 26 items and ranged from 0 (no impairment) to 104 (severe impairment). A higher score indicated greater impairment. LS mean and SE were calculated using MMRM.
Time frame: Baseline, Weeks 48 and 72
Change From Baseline in the Modified UMSARS Part I (mUMSARS) Score at the EOT DBP
UMSARS Part 1 assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items) rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. The modified UMSARS part I (mUMSARS) score was derived by collapsing the response option 0 and 1 within each item (0 \& 1 =1). Hence, the mUMSARS score ranged from 12 to 48 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.
Time frame: Baseline, Weeks 48 and 72
Change From Baseline in the UMSARS Part I Scores at the EOT DBP
UMSARS Part 1 assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items: speech, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function, and bowel function) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. Part I total score ranged between 0 to 48 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.
Time frame: Baseline, Weeks 48 and 72
Change From Baseline in the UMSARS Part II Scores at the EOT DBP
UMSARS Part II consists of a clinical examination of key MSA motor signs and symptoms (14 items: facial expression, speech, ocular motor dysfunction, tremor at rest, action tremor, increased tone, rapid alternating movements of hands, finger taps, leg agility, heel-knee-shin test, arising from chair, posture, body sway, gait) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. Part II total score ranged between 0 and 56 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.
Time frame: Baseline, Weeks 48 and 72
Change From Baseline in Schwab and England Activities of Daily Living (SE-ADL) Score at Week 48 in the DBP
The SE-ADL is a combined participant- and clinician-reported scale to assess participants physical functioning in activities in daily living to grade functional status. For this study, only the clinician-rated part was administered. The SE-ADL scale uses percentages to represent how much effort and dependence on others, participants need to complete daily chores. The SE-ADL scale ranged from 0% indicating worst possible function (fully dependent) to 100% indicating no impairment (completely independent). LS mean and SE were calculated using MMRM.
Time frame: Baseline, Week 48
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 48 in the DBP
The CGI-S was administered by an experienced neurologist familiar with MSA participants to make an expert clinical global judgement about the severity of the disease across various time points. The rating was based upon observed and reported symptoms, behaviour, and function in the past seven days. The CGI-S was rated on a scale ranging from 0 to 4 (whereas the 0 = normal, not impaired; 1 = mildly impaired; 2 = moderately impaired; 3 = severely impaired; 4 = extremely impaired). LS mean and SE were calculated using MMRM.
Time frame: Baseline, Week 48
Change From Baseline in Patient Global Impression - Severity of Illness (PGI-S) Score at Week 48 in the DBP
The PGI-S is a self-reported single item to evaluate all aspects of participants' MSA symptoms. Participants were asked to choose the response that best described the severity of their MSA symptoms over the past week. The question was rated on a 5-point scale ranging from 0 to 4 (0 = none; 1 = minor; 2 = moderate; 3 = severe; 4 = very severe). LS mean and SE were calculated using MMRM.
Time frame: Baseline, Week 48
Change From Baseline in Observer-Reported Global Impression - Severity of Illness (OGI-S) Score at Week 48 in the DBP
The OGI-S is a single-question carer/observer-reported outcome to evaluate all aspects of participants' MSA symptoms. Carer/observers were asked to choose the response that best described the observed severity of MSA symptoms in the person they care for over the past week. The question was rated on a 5-point scale ranging from 0 to 4 (0 = none; 1 = minor; 2 = moderate; 3 = severe; 4 = very severe). LS mean and SE were calculated using MMRM.
Time frame: Baseline, Week 48
Composite Autonomic Symptom Score Select Change (COMPASS Select Change) Total Score at Week 48 in the DBP
The COMPASS Select, a participant-reported scale, consists of a subset of 36 items derived from the original COMPASS, to assess severity of autonomic symptoms in MSA during the last year. The COMPASS Select includes 3 domains related to blood pressure control: syncope, orthostatic intolerance, and vasomotor symptoms; and 3 domains focused on symptoms of disturbed secretomotor, bladder, and sleep function. The COMPASS Select Change is a derivate of COMPASS Select, consisting of 16 items in which participants were asked to score their change in autonomic symptoms since their last visit. The scoring algorithm of COMPASS was highly complicated and required computer analysis for score generation. COMPASS Change Select score ranged from -150 to 150. A higher score indicated greater autonomic symptom severity.
Time frame: Week 48
Change From Baseline in UMSARS Part IV Score at Week 48 in the DBP
The UMSARS part IV comprised a global disability scale ranging from 1-5, with 1 = 'Completely independent. Able to do all chores with minimal difficulty or impairment. Essentially normal. Unaware of any difficulty'; 2 = 'Not completely independent. Needs help with some chores'; 3 = 'More dependent. Help with half of chores. Spends a large part of the day with chores'; 4 = 'Very dependent. Now and then does a few chores alone or begins alone. Much help needed'; and 5 = 'Totally dependent and helpless. Bedridden'. LS mean and SE were calculated using MMRM.
Time frame: Baseline, Week 48
Change From Baseline in Speech, Swallowing, Falls, and Walking, as Assessed by the UMSARS Part I Item Scores at Week 48 in the DBP
UMSARS Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items: speech, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function, and bowel function) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. LS mean and SE were calculated using MMRM.
Time frame: Baseline, Week 48
Change From Baseline in Number of Falls, as Assessed by the Fall Diary Periods (Weeks 44 to 48) in the DBP
Fall Diary period was defined as the period between the two visits where the diary was filled out according to the protocol. LS mean and SE were calculated using MMRM.
Time frame: Baseline, Weeks 44 to 48
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Score at Week 48 in the DBP
The EQ-5D-5L is a participant-reported assessment designed to measure the participant's wellbeing. It consisted of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analogue scale (VAS) of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). LS mean and SE were calculated using MMRM.
Time frame: Baseline, Week 48
Percent Change From Baseline in Brain Volume With Ventricles, as Measured by Volumetric MRI (vMRI) at Week 48 in the DBP
LS mean and SE were calculated using MMRM.
Time frame: Baseline, Week 48
Percent Change From Baseline in P-Neurofilament Light Chain (NfL) Protein Concentration at Week 48 in the DBP
LS mean and SE were calculated using MMRM.
Time frame: Baseline, Week 48
Lu AF82422 Plasma Concentration in the DBP
Time frame: Weeks 0, 4, 6, 8, 12, 24, 36, 48, 60, 72, 88
Lu AF82422 Cerebrospinal Fluid (CSF) Concentrations in the DBP
Time frame: Weeks 0 and 48
Lu AF82422 CSF/Plasma Concentration Ratio in the DBP
Time frame: Weeks 0 and 48
This study included a Placebo-controlled Double-blind Period (DBP) (48 weeks up to 72 weeks) and an Optional Open-label Extension (OLE) Period (96 weeks). Individual participant End of Trial (EOT) DBP will vary from 48 to 72 weeks. Once the last participant reaches week 48, the remaining participants will have their next scheduled visit converted to EOT DBP.
| Milestone | Placebo | Lu AF82422 |
|---|---|---|
| Started | 22 | 42 |
| Received at least 1 dose of study drug | 21 | 40 |
| Completed | 16 | 32 |
| Not completed | 6 | 10 |
| Withdrew: Randomized but not treated | 1 | 2 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Other than specified | 0 | 3 |
The primary endpoint assessed disease progression by a Bayesian repeated measures model on UMSARS TS. Reported here is the estimated slowing (%) of clinical progression in participants receiving Lu AF82422 relative to those receiving placebo. UMSARS is a combined clinician and patient-reported outcome assessment developed to provide a surrogate measure of disease progression in multiple system atrophy (MSA). UMSARS TS was obtained by the sum of the items from Part I and Part II. Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks and Part II consists of a clinical examination of key MSA motor signs and symptoms. UMSARS TS score was the sum of all items and ranged from 0 (no impairment) to 104 (severe impairment). A higher score indicated greater impairment.
| Percentage Slowing of Clin. Progression | Lu AF82422 or Placebo |
|---|---|
| Percentage Slowing of Clinical Progression Based on Change From Baseline in the UMSARS TS at the End of Treatment (EOT) DB Period (DBP) | 19 |
UMSARS is a combined clinician and patient-reported scale to assess motor impairment in MSA participants. UMSARS TS was obtained by the sum of the items from Part I and Part II. Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks (12 items) rated on a scale ranging from 0 = not affected to 4 = unable to do the activity. Part I total score ranged between 0 to 48 (higher score indicated greater impairment). Part II consists of a clinical examination of key MSA motor signs and symptoms (14 items) rated on a scale ranging from 0 = normal to 4 = marked/severe impairment. Part II total score ranged between 0 and 56 (higher score indicated greater impairment). UMSARS TS score was the sum of all 26 items and ranged from 0 (no impairment) to 104 (severe impairment). A higher score indicated greater impairment. LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Change at Week 48 | 13.93 ± 3.42 | 13.32 ± 2.86 |
| Change at Week 72 | 19.13 ± 3.74 | 15.10 ± 3.00 |
UMSARS Part 1 assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items) rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. The modified UMSARS part I (mUMSARS) score was derived by collapsing the response option 0 and 1 within each item (0 \& 1 =1). Hence, the mUMSARS score ranged from 12 to 48 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Change at Week 48 | 7.07 ± 1.62 | 6.48 ± 1.33 |
| Change at Week 72 | 8.40 ± 2.00 | 8.77 ± 1.44 |
UMSARS Part 1 assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items: speech, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function, and bowel function) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. Part I total score ranged between 0 to 48 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Change at Week 48 | 7.64 ± 1.92 | 6.98 ± 1.59 |
| Change at Week 72 | 8.49 ± 2.21 | 10.23 ± 1.65 |
UMSARS Part II consists of a clinical examination of key MSA motor signs and symptoms (14 items: facial expression, speech, ocular motor dysfunction, tremor at rest, action tremor, increased tone, rapid alternating movements of hands, finger taps, leg agility, heel-knee-shin test, arising from chair, posture, body sway, gait) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. Part II total score ranged between 0 and 56 (higher score indicated greater impairment). LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Change at Week 48 | 7.16 ± 2.15 | 6.76 ± 1.83 |
| Change at Week 72 | 10.24 ± 2.38 | 7.10 ± 1.93 |
The SE-ADL is a combined participant- and clinician-reported scale to assess participants physical functioning in activities in daily living to grade functional status. For this study, only the clinician-rated part was administered. The SE-ADL scale uses percentages to represent how much effort and dependence on others, participants need to complete daily chores. The SE-ADL scale ranged from 0% indicating worst possible function (fully dependent) to 100% indicating no impairment (completely independent). LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Change From Baseline in Schwab and England Activities of Daily Living (SE-ADL) Score at Week 48 in the DBP | -23.56 ± 7.40 | -20.82 ± 6.52 |
The CGI-S was administered by an experienced neurologist familiar with MSA participants to make an expert clinical global judgement about the severity of the disease across various time points. The rating was based upon observed and reported symptoms, behaviour, and function in the past seven days. The CGI-S was rated on a scale ranging from 0 to 4 (whereas the 0 = normal, not impaired; 1 = mildly impaired; 2 = moderately impaired; 3 = severely impaired; 4 = extremely impaired). LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 48 in the DBP | 0.58 ± 0.17 | 0.34 ± 0.14 |
The PGI-S is a self-reported single item to evaluate all aspects of participants' MSA symptoms. Participants were asked to choose the response that best described the severity of their MSA symptoms over the past week. The question was rated on a 5-point scale ranging from 0 to 4 (0 = none; 1 = minor; 2 = moderate; 3 = severe; 4 = very severe). LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Change From Baseline in Patient Global Impression - Severity of Illness (PGI-S) Score at Week 48 in the DBP | -0.07 ± 0.21 | 0.18 ± 0.18 |
The OGI-S is a single-question carer/observer-reported outcome to evaluate all aspects of participants' MSA symptoms. Carer/observers were asked to choose the response that best described the observed severity of MSA symptoms in the person they care for over the past week. The question was rated on a 5-point scale ranging from 0 to 4 (0 = none; 1 = minor; 2 = moderate; 3 = severe; 4 = very severe). LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Change From Baseline in Observer-Reported Global Impression - Severity of Illness (OGI-S) Score at Week 48 in the DBP | 0.36 ± 0.22 | 0.20 ± 0.18 |
The COMPASS Select, a participant-reported scale, consists of a subset of 36 items derived from the original COMPASS, to assess severity of autonomic symptoms in MSA during the last year. The COMPASS Select includes 3 domains related to blood pressure control: syncope, orthostatic intolerance, and vasomotor symptoms; and 3 domains focused on symptoms of disturbed secretomotor, bladder, and sleep function. The COMPASS Select Change is a derivate of COMPASS Select, consisting of 16 items in which participants were asked to score their change in autonomic symptoms since their last visit. The scoring algorithm of COMPASS was highly complicated and required computer analysis for score generation. COMPASS Change Select score ranged from -150 to 150. A higher score indicated greater autonomic symptom severity.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Composite Autonomic Symptom Score Select Change (COMPASS Select Change) Total Score at Week 48 in the DBP | 18.79 ± 41.98 | 34.28 ± 26.86 |
The UMSARS part IV comprised a global disability scale ranging from 1-5, with 1 = 'Completely independent. Able to do all chores with minimal difficulty or impairment. Essentially normal. Unaware of any difficulty'; 2 = 'Not completely independent. Needs help with some chores'; 3 = 'More dependent. Help with half of chores. Spends a large part of the day with chores'; 4 = 'Very dependent. Now and then does a few chores alone or begins alone. Much help needed'; and 5 = 'Totally dependent and helpless. Bedridden'. LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Change From Baseline in UMSARS Part IV Score at Week 48 in the DBP | 1.35 ± 0.35 | 1.13 ± 0.30 |
UMSARS Part I assesses historical information on symptoms and activities of daily living over the past 2 weeks as reported by participants and caregivers (12 items: speech, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function, and bowel function) each rated on a scale ranging from 0 to 4; with 0 = not affected/normal 1= mildly affected/impaired, 2= moderately affected/impaired, 3= severely affected/impaired, and 4 = helpless or entirely affected/impaired. LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Speech | 0.61 ± 0.26 | 0.19 ± 0.21 |
| Swallowing | 0.57 ± 0.30 | 0.91 ± 0.25 |
| Falls | 0.36 ± 0.42 | 0.22 ± 0.36 |
| Walking | 1.02 ± 0.27 | 0.86 ± 0.23 |
Fall Diary period was defined as the period between the two visits where the diary was filled out according to the protocol. LS mean and SE were calculated using MMRM.
| falls | Placebo | Lu AF82422 |
|---|---|---|
| Change From Baseline in Number of Falls, as Assessed by the Fall Diary Periods (Weeks 44 to 48) in the DBP | -0.18 ± 0.05 | -0.16 ± 0.04 |
The EQ-5D-5L is a participant-reported assessment designed to measure the participant's wellbeing. It consisted of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analogue scale (VAS) of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). LS mean and SE were calculated using MMRM.
| units on a scale | Placebo | Lu AF82422 |
|---|---|---|
| Mobility Score | 0.75 ± 0.32 | 0.49 ± 0.28 |
| Self Care Score | 0.80 ± 0.38 | 0.74 ± 0.32 |
| Usual Activities Score | 0.50 ± 0.39 | 0.87 ± 0.34 |
| Pain/Discomfort Score | -0.06 ± 0.38 | 0.22 ± 0.33 |
| Anxiety/Depression Score | 0.05 ± 0.29 | 0.34 ± 0.25 |
| VAS Score | -13.16 ± 6.46 | -13.80 ± 5.74 |
LS mean and SE were calculated using MMRM.
| percent change | Placebo | Lu AF82422 |
|---|---|---|
| Percent Change From Baseline in Brain Volume With Ventricles, as Measured by Volumetric MRI (vMRI) at Week 48 in the DBP | -1.14 ± 0.39 | -0.81 ± 0.33 |
LS mean and SE were calculated using MMRM.
| percent change | Placebo | Lu AF82422 |
|---|---|---|
| Percent Change From Baseline in P-Neurofilament Light Chain (NfL) Protein Concentration at Week 48 in the DBP | 10.37 ± 11.60 | 6.81 ± 10.01 |
| nanograms (ng)/milliliter (mL) | Lu AF82422 |
|---|---|
| Week 0 | NA ± NA |
| Week 4 | 186754 ± 63989 |
| Week 6 | 408806 ± 148195 |
| Week 8 | 285079 ± 170320 |
| Week 12 | 312451 ± 128006 |
| Week 24 | 418385 ± 349787 |
| Week 36 | 417758 ± 170012 |
| Week 48 | 390751 ± 181489 |
| Week 60 | 526706 ± 312743 |
| Week 72 | 544071 ± 355696 |
| Safety Follow Up (Week 88) | 42425 ± 18372 |
| ng/mL | Lu AF82422 |
|---|---|
| Week 0 | 5 ± 0 |
| Week 48 | 1531 ± 886 |
| ratio | Lu AF82422 |
|---|---|
| Week 0 | 25.00 ± 0.00 |
| Week 48 | 0.40 ± 0.21 |
Collected over From date of first dose up to Week 88. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 2/21 (9.5%) | 7/21 (33.3%) | 14/21 (66.7%) |
| Lu AF82422 | 2/40 (5%) | 12/40 (30%) | 34/40 (85%) |
| Event | Placebo | Lu AF82422 |
|---|---|---|
| UrosepsisInfections and infestations | 0/21 | 2/40 |
| Cardio-respiratory arrestCardiac disorders | 1/21 | 0/40 |
| COVID-19Infections and infestations | 1/21 | 1/40 |
| SepsisInfections and infestations | 1/21 | 0/40 |
| Urinary tract infectionInfections and infestations | 1/21 | 1/40 |
| FallInjury, poisoning and procedural complications | 1/21 | 1/40 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/21 | 0/40 |
| Pelvic fractureInjury, poisoning and procedural complications | 1/21 | 0/40 |
| Back painMusculoskeletal and connective tissue disorders | 1/21 | 0/40 |
| Facet joint syndromeMusculoskeletal and connective tissue disorders | 1/21 | 0/40 |
| Event | Placebo | Lu AF82422 |
|---|---|---|
| COVID-19Infections and infestations | 5/21 | 10/40 |
| Back painMusculoskeletal and connective tissue disorders | 2/21 | 6/40 |
| HeadacheNervous system disorders | 1/21 | 5/40 |
| Oedema peripheralGeneral disorders | 1/21 | 4/40 |
| Urinary tract infectionInfections and infestations | 2/21 | 4/40 |
| HypertensionVascular disorders | 0/21 | 4/40 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/21 | 0/40 |
| FatigueGeneral disorders | 2/21 | 3/40 |
| Injection site extravasationGeneral disorders | 2/21 | 1/40 |
| Seasonal allergyImmune system disorders | 2/21 | 0/40 |
All-patients-treated set (APTS) included all randomized participants who took at least 1 dose of double-blind investigational medicinal product (IMP).
| Age, Continuous(years) | Placebo | Lu AF82422 | Total |
|---|---|---|---|
| Mean | 59.8 ± 6.85 | 61.4 ± 8.09 | 60.8 ± 7.67 |
| Sex: Female, Male(Participants) | Placebo | Lu AF82422 | Total |
|---|---|---|---|
| Female | 10 | 19 | 29 |
| Male | 11 | 21 | 32 |
| Race (NIH/OMB)(Participants) | Placebo | Lu AF82422 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 12 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 15 | 26 | 41 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Unified Multiple System Atrophy Rating Scale (UMSARS) Part I and Part II Total Score (UMSARS TS)(units on a scale) | Placebo | Lu AF82422 | Total |
|---|---|---|---|
| Mean | 37 ± 7.77 | 34.8 ± 9 | 35.5 ± 8.59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2021 to primary completion in Nov 2023, 24 months.
Results were first posted in Dec 2024, 1 year 1 month after primary completion.
Of 19 phase 2 interventional studies under Multiple System Atrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 32. This study's 24 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlenetug